The FGF21-adiponectin axis in controlling energy and vascular homeostasis

Journal of Molecular Cell Biology

Volumn 8, Issue 2, 2016, Pages 110-119

  Hui, Xiaoyan ^a,b   Feng, Tianshi ^a,b   Liu, Qing ^a,b   Gao, Yuan ^a,b   Xu, Aimin ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

adiponectin; energy metabolism; FGF21; PPAR ; vascular homeostasis

Indexed keywords

ADIPONECTIN; FIBROBLAST GROWTH FACTOR 21; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; FIBROBLAST GROWTH FACTOR;

ADIPOCYTE; ENERGY EXPENDITURE; ENERGY METABOLISM; GLUCOSE HOMEOSTASIS; HOMEOSTASIS; HUMAN; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; VASCULAR HOMEOSTASIS; ANIMAL; BLOOD VESSEL; METABOLISM; SIGNAL TRANSDUCTION;

ADIPONECTIN; ANIMALS; BLOOD VESSELS; ENERGY METABOLISM; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; SIGNAL TRANSDUCTION;

EID: 84965058133     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjw013     Document Type: Review

References (97)

1. Adams, A.C., Cheng, C.C., Coskun, T., et al. (2012a). FGF21 requires bklotho to act in vivo. PLoS One 7, e49977.
2. Adams, A.C., Yang, C., Coskun, T., et al. (2012b). The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2, 31-37.
3. Arner, P., Pettersson, A., Mitchell, P.J., et al. (2008). FGF21 attenuates lipolysis in human adipocytes - apossible link to improved insulin sensitivity. FEBS Lett. 582, 1725-1730.
4. Badman, M.K., Pissios, P., Kennedy, A.R., et al. (2007). Hepatic fibroblast growth factor 21 is regulated by PPARa and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5, 426-437.
5. Berg, A.H., Combs, T.P., Du, X., et al. (2001). The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7, 947-953.
6. Bookout, A.L., de Groot, M.H., Owen, B.M., et al. (2013). FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat. Med. 19, 1147-1152.
7. Brown, M.S., and Goldstein, J.L. (1997). The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331-340.
8. Chow, W.S., Xu, A., Woo, Y.C., et al. (2013). Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler. Thromb. Vasc. Biol. 33, 2454-2459.
9. Diaz-Delfin, J., Hondares, E., Iglesias, R., et al. (2012). TNF-a represses b-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 153, 4238-4245.
10. Ding, X., Boney-Montoya, J., Owen, B.M., et al. (2012). bKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 16, 387-393.
11. Do, H.T., Tselykh, T.V., Makela, J., et al. (2012). Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap). J. Biol. Chem. 287, 12602-12611.
12. Dong, J.Q., Rossulek, M., Somayaji, V.R., et al. (2015). Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. Br. J. Clin. Pharmacol. 80, 1051-1063.
13. Dutchak, P.A., Katafuchi, T., Bookout, A.L., et al. (2012). Fibroblast growth factor-21 regulates PPARg activity and the antidiabetic actions of thiazolidinediones. Cell 148, 556-567.
14. Fasshauer, M., Kralisch, S., Klier, M., et al. (2003). Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 301, 1045-1050.
15. Fisher, F.M., Estall, J.L., Adams, A.C., et al. (2011). Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 152, 2996-3004.
16. Fisher, F.M., Kleiner, S., Douris, N., et al. (2012). FGF21 regulates PGC-1a and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 26, 271-281.
17. Foltz, I.N., Hu, S., King, C., et al. (2012). Treating diabetes and obesity with an FGF21-mimetic antibody activating the bKlotho/FGFR1c receptor complex. Sci. Transl. Med. 4, 162ra153.
18. Fon Tacer, K., Bookout, A.L., Ding, X., et al. (2010). Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 24, 2050-2064.
19. Fruebis, J., Tsao, T.S., Javorschi, S., et al. (2001). Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl Acad. Sci. USA 98, 2005-2010.
20. Fu, Y., Luo, N., Klein, R.L., et al. (2005). Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J. Lipid Res. 46, 1369-1379.
21. Gaich, G., Chien, J.Y., Fu, H., et al. (2013). The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18, 333-340.
22. Ge, X., Chen, C., Hui, X., et al. (2011). Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/ Ets-like protein-1 in adipocytes. J. Biol. Chem. 286, 34533-34541.
23. Han, X., Chen, C., Cheng, G., et al. (2015). Serum fibroblast growth factor 21 levels are increased in atrial fibrillation patients. Cytokine 73, 176-180.
24. Hansen, J., Brandt, C., Nielsen, A.R., et al. (2011). Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine. Endocrinology 152, 164-171.
25. Holland, W.L., Adams, A.C., Brozinick, J.T., et al. (2013). An FGF21-adiponectinceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 17, 790-797.
26. Horton, J.D., Goldstein, J.L., and Brown, M.S. (2002). SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131.
27. Hotta, Y., Nakamura, H., Konishi, M., et al. (2009). Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 150, 4625-4633.
28. Hsuchou, H., Pan, W., and Kastin, A.J. (2007). The fasting polypeptide FGF21 can enter brain from blood. Peptides 28, 2382-2386.
29. Hu, E., Liang, P., and Spiegelman, B.M. (1996). AdipoQ is a novel adiposespecific gene dysregulated in obesity. J. Biol. Chem. 271, 10697-10703.
30. Hui, X., Lam, K.S., Vanhoutte, P.M., et al. (2012). Adiponectin and cardiovascular health: an update. Br. J. Pharmacol. 165, 574-590.
31. Hui, X., Gu, P., Zhang, J., et al. (2015). Adiponectin enhances cold-induced browning of subcutaneous adipose tissue via promotingM2 macrophage proliferation. Cell Metab. 22, 279-290.
32. Inagaki, T., Dutchak, P., Zhao, G., et al. (2007). Endocrine regulation of the fasting response by PPARa-mediated induction of fibroblast growth factor 21. Cell Metab. 5, 415-425.
33. Joki, Y., Ohashi, K., Yuasa, D., et al. (2015). FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectindependent mechanism. Biochem. Biophys. Res. Commun. 459, 124-130.
34. Kharitonenkov, A., Shiyanova, T.L., Koester, A., et al. (2005). FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627-1635.
35. Kharitonenkov, A., Wroblewski, V.J., Koester, A., et al. (2007). The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148, 774-781.
36. Kharitonenkov, A., Dunbar, J.D., Bina, H.A., et al. (2008). FGF-21/FGF-21 receptor interaction and activation is determined by bKlotho. J. Cell. Physiol. 215, 1-7.
37. Kim, J.Y., van de Wall, E., Laplante, M., et al. (2007). Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 117, 2621-2637.
38. Li, C.J., Sun, H.W., Zhu, F.L., et al. (2007). Local adiponectin treatment reduces atherosclerotic plaque size in rabbits. J. Endocrinol. 193, 137-145.
39. Li, X., Hassoun, H.T., Santora, R., et al. (2009). Organ crosstalk: the role of the kidney. Curr. Opin. Crit. Care 15, 481-487.
40. Liang, Q., Zhong, L., Zhang, J., et al. (2014). FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 63, 4064-4075.
41. Lin, Z., Wu, Z., Yin, X., et al. (2010). Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 5, e15534.
42. Lin, Z., Tian, H., Lam, K.S., et al. (2013). Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 17, 779-789.
43. Lin, X.L., He, X.L., Zeng, J.F., et al. (2014). FGF21 increases cholesterol efflux by upregulating ABCA1 through the ERK1/2-PPARg-LXRa pathway in THP1 macrophage-derived foam cells. DNA Cell Biol. 33, 514-521.
44. Lin, Z., Pan, X., Wu, F., et al. (2015). Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation 131, 1861-1871.
45. Liu, M., and Liu, F. (2010). Transcriptional and post-translational regulation of adiponectin. Biochem. J. 425, 41-52.
46. Liu, M., Zhou, L., Xu, A., et al. (2008). A disulfide-bond A oxidoreductase-like protein (DsbA-L) regulates adiponectin multimerization. Proc. Natl Acad. Sci. USA 105, 18302-18307.
47. Liu, S.Q., Roberts, D., Kharitonenkov, A., et al. (2013). Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci. Rep. 3, 2767.
48. Maeda, K., Okubo, K., Shimomura, I., et al. (1996). cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem. Biophys. Res. Commun. 221, 286-289.
49. Maeda, N., Takahashi, M., Funahashi, T., et al. (2001). PPARg ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50, 2094-2099.
50. Mandal, P., Pratt, B.T., Barnes, M., et al. (2011). Molecular mechanism for adiponectin-dependentM2 macrophage polarization: link between the metabolic and innate immune activity of full-length adiponectin. J. Biol. Chem. 286, 13460-13469.
51. Markan, K.R., Naber, M.C., Ameka, M.K., et al. (2014). Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63, 4057-4063.
52. Nakano, Y., Tobe, T., Choi-Miura, N.H., et al. (1996). Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J. Biochem. 120, 803-812.
53. Nawrocki, A.R., Rajala, M.W., Tomas, E., et al. (2006). Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor g agonists. J. Biol. Chem. 281, 2654-2660.
54. Nishimura, T., Nakatake, Y., Konishi, M., et al. (2000). Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 1492, 203-206.
55. Novotny, D., Vaverkova, H., Karasek, D., et al. (2014). Evaluation of total adiponectin, adipocyte fatty acid binding protein and fibroblast growth factor 21 levels in individuals with metabolic syndrome. Physiol. Res. 63, 219-228.
56. Ogawa, Y., Kurosu, H., Yamamoto, M., et al. (2007). bKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl Acad. Sci. USA 104, 7432-7437.
57. Okamoto, Y., Kihara, S., Ouchi, N., et al. (2002). Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106, 2767-2770.
58. Owen, B.M., Bookout, A.L., Ding, X., et al. (2013). FGF21 contributes to neuroendocrine control of female reproduction. Nat. Med. 19, 1153-1156.
59. Owen, B.M., Ding, X., Morgan, D.A., et al. (2014). FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 20, 670-677.
60. Patel, V., Adya, R., Chen, J., et al. (2014). Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PLoS One 9, e87102.
61. Pedersen, L., and Hojman, P. (2012). Muscle-to-organ cross talk mediated by myokines. Adipocyte 1, 164-167.
62. Planavila, A., Redondo, I., Hondares, E., et al. (2013). Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat. Commun. 4, 2019.
63. Planavila, A., Redondo-Angulo, I., Ribas, F., et al. (2015). Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc. Res. 106, 19-31.
64. Potthoff, M.J., Inagaki, T., Satapati, S., et al. (2009). FGF21 induces PGC-1a and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl Acad. Sci. USA 106, 10853-10858.
65. Qiao, L., Kinney, B., Schaack, J., et al. (2011). Adiponectin inhibits lipolysis in mouse adipocytes. Diabetes 60, 1519-1527.
66. Romacho, T., Elsen, M., Rohrborn, D., et al. (2014). Adipose tissue and its role in organ crosstalk. Acta Physiol. 210, 733-753.
67. Scherer, P.E. (2006). Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 55, 1537-1545.
68. Scherer, P.E., Williams, S., Fogliano, M., et al. (1995). A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 270, 26746-26749.
69. Schraw, T., Wang, Z.V., Halberg, N., et al. (2008). Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology 149, 2270-2282.
70. Sharabi, Y., Oron-Herman, M., Kamari, Y., et al. (2007). Effect of PPAR-g agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model. Am. J. Hypertens. 20, 206-210.
71. Shen, Y., Ma, X., Zhou, J., et al. (2013). Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc. Diabetol. 12, 124.
72. Shioji, K., Moriguchi, A., Moriwaki, S., et al. (2005). Hypoadiponectinemia implies the development of atherosclerosis in carotid and coronary arteries. J. Cardiol. 46, 105-112.
73. Soares, A.F., Guichardant, M., Cozzone, D., et al. (2005). Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic. Biol. Med. 38, 882-889.
74. Suzuki, M., Uehara, Y., Motomura-Matsuzaka, K., et al. (2008). bKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol. 22, 1006-1014.
75. Tang, H., Sebastian, B.M., Axhemi, A., et al. (2012). Ethanol-induced oxidative stress via the CYP2E1 pathway disrupts adiponectin secretion from adipocytes. Alcohol. Clin. Exp. Res. 36, 214-222.
76. Tilg, H., and Moschen, A.R. (2006). Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6, 772-783.
77. Trayhurn, P., and Wood, I.S. (2004). Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br. J. Nutr. 92, 347-355.
78. Veniant, M.M., Hale, C., Helmering, J., et al. (2012a). FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One 7, e40164.
79. Veniant, M.M., Komorowski, R., Chen, P., et al. (2012b). Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 153, 4192-4203.
80. Wang, Y., Xu, A., Knight, C., et al. (2002). Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J. Biol. Chem. 277, 19521-19529.
81. Wang, Z.V., Schraw, T.D., Kim, J.Y., et al. (2007). Secretion of the adipocytespecific secretory protein adiponectin critically depends on thiol-mediated protein retention. Mol. Cell. Biol. 27, 3716-3731.
82. Wang, Y., Lam, K.S., Yau, M.H., et al. (2008). Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem. J. 409, 623-633.
83. Wang, C.H., Wang, C.C., Huang, H.C., et al. (2013). Mitochondrial dysfunction leads to impairment of insulin sensitivity and adiponectin secretion in adipocytes. FEBS J. 280, 1039-1050.
84. Wedellova, Z., Dietrich, J., Siklova-Vitkova, M., et al. (2011). Adiponectin inhibits spontaneous and catecholamine-induced lipolysis in human adipocytes of non-obese subjects through AMPK-dependent mechanisms. Physiol. Res. 60, 139-148.
85. Weisberg, S.P., McCann, D., Desai, M., et al. (2003). Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796-1808.
86. Wolf, A.M., Wolf, D., Rumpold, H., et al. (2004). Adiponectin induces the antiinflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun. 323, 630-635.
87. Woo, Y.C., Xu, A., Wang, Y., et al. (2013). Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin. Endocrinol. 78, 489-496.
88. Wu, X., Motoshima, H., Mahadev, K., et al. (2003). Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52, 1355-1363.
89. Wu, X., Qi, Y.F., Chang, J.R., et al. (2015). Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stressmediated apoptosis in apoE(-/-) mice. Heart Vessels 30, 657-668.
90. Xu, H., Barnes, G.T., Yang, Q., et al. (2003). Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821-1830.
91. Xu, A., Wang, Y., Xu, J.Y., et al. (2006). Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin. Chem. 52, 405-413.
92. Xu, J., Lloyd, D.J., Hale, C., et al. (2009a). Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250-259.
93. Xu, J., Stanislaus, S., Chinookoswong, N., et al. (2009b). Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models - association with liver and adipose tissue effects. Am. J. Physiol. Endocrinol. Metab. 297, E1105-E1114.
94. Yamauchi, T., and Kadowaki, T. (2008). Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int. J. Obes. 32(Suppl 7), S13-S18.
95. Yamauchi, T., Kamon, J., Minokoshi, Y., et al. (2002). Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288-1295.
96. Ye, D., Wang, Y., Li, H., et al. (2014). Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1a-mediated antioxidant capacity in mice. Hepatology 60, 977-989.
97. Zhang, X., Yeung, D.C., Karpisek, M., et al. (2008). Serum FGF21 levels are increased in obesityand are independently associated with the metabolic syndrome in humans. Diabetes 57, 1246-1253.